Join our community of smart investors

Oxford BioDynamics attracts the big guns of global pharma

Since joining the London stock market in October 2016, the genetics specialist has signed partnerships with five of the top 30 global pharma companies
Oxford BioDynamics attracts the big guns of global pharma

Announcements have gushed out of the press office of genetics specialist Oxford BioDynamics (OBD) in the last six months and investors have started to take notice. The shares hit a record high of 279p in October after the group’s proprietary biotechnology platform EpiSwitch was successful is diagnosing breast cancer, earned patent approval in the US, and began to generate commercial interest in Asia. Recently signed partnerships with two major US pharma companies have created optimism that OBD and EpiSwitch could play an important role in the future of personalised medicine.

IC TIP: Buy at 188p

To continue reading...
OR
Register for free
Read 3 articles for free each month
* Excl. premium articles
Have an account? Sign in